Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2022-04-22 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
2021年度内部控制的自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report for the year 2021 by 美康生物科技股份有限公司. It discusses the company's internal control evaluation, scope, standards for identifying control deficiencies, and conclusions about the effectiveness of internal controls. The content is detailed and specific to internal control evaluation rather than a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to internal controls, excluding full annual reports. Therefore, the document is best classified as AR with high confidence. FY 2021
2022-04-22 Chinese
关于举行2021年度网上业绩说明会及征集相关问题的公告
Investor Presentation Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the scheduling of a 2021 annual performance online briefing (业绩说明会) and the solicitation of related questions from investors. It references the 2021 annual report having been approved and disclosed on April 23, 2022, but does not contain the report itself or detailed financial data. The document invites investors to participate in the online briefing and submit questions. The length is short (980 characters), and the content is clearly an announcement about an event related to the annual report, not the report itself. Therefore, it fits the category of Investor Presentation (IP) as it is a detailed presentation event for investors focusing on financials and company performance.
2022-04-22 Chinese
关于2021年度计提资产减值准备的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the company's asset impairment provisions for the fiscal year 2021. It details the reasons, scope, amounts, and accounting methods for the impairment provisions, including bad debt, inventory write-downs, goodwill impairment, and long-term asset impairment. The document includes specific financial figures and accounting standards references. It is not a full annual report or interim report but a specific announcement about asset impairment provisions. The document is relatively short (3497 characters) and is a formal announcement of accounting estimates and provisions, not a full financial statement or report. It does not fit categories like Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a certification or regulatory filing in the narrow sense. The content is focused on audit-related accounting estimates and impairment testing, which aligns with an Audit Report / Information (AR) category, as it discusses the application of accounting principles and impairment testing results. Therefore, the best classification is Audit Report / Information (AR). FY 2021
2022-04-22 Chinese
关于续聘2022年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the auditing firm (立信会计师事务所) for the fiscal year 2022. It details the qualifications, past performance, and independence of the auditor, as well as the approval process by the board and audit committee. It does not contain any actual financial statements or audit reports but rather informs shareholders and the public about the intention to continue with the same auditor and the related governance procedures. The document length is 4666 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit matters but is not the full audit report itself, nor is it a regulatory filing or a report publication announcement. However, since it is primarily an announcement about the auditor appointment and not the audit report itself, it fits best under AR (Audit Report / Information). FY 2022
2022-04-22 Chinese
2021年年度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (456 characters) indicating that the company's 2021 Annual Report and its summary have been approved and published on the official disclosure website. It does not contain the actual annual report or financial data but rather informs investors where to find the full report. According to the 'Menu vs Meal' rule, such a brief notice about the report's availability is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2022-04-22 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 4th Board of Directors of 美康生物科技股份有限公司. It includes approvals of the 2021 annual general manager work report, board work report, 2021 annual report and its summary, 2021 financial statements, profit distribution plan, internal control self-evaluation report, fundraising usage report, 2022 financing plan, remuneration and assessment plans for directors and senior management, reappointment of the audit firm, amendments to company bylaws, and the scheduling of the 2021 annual general meeting. The document is a formal board meeting resolution announcement, not the actual annual report or financial statements themselves. It references that the detailed reports are published on the designated stock exchange website. The document length is about 4924 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full annual report. Therefore, this document is best classified as a Board/Management Information (MANG) filing, as it announces board decisions and management reports approval rather than containing the full reports themselves.
2022-04-22 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.